Activation of the unfolded protein response bypasses trastuzumab-mediated inhibition of the PI-3K pathway

Cancer Letters

Volumn 329, Issue 2, 2013, Pages 236-242

  Kumandan, Sreekanth ^a   Mahadevan, Navin R ^a   Chiu, Kevin ^a   DeLaney, Alexandra ^a   Zanetti, Maurizio ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

ER stress; Lipocalin 2; Tumorigenesis

Indexed keywords

NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SECRETION; UNFOLDED PROTEIN RESPONSE; UPREGULATION;

ACUTE-PHASE PROTEINS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; HEAT-SHOCK PROTEINS; HUMANS; IMIDAZOLES; LIPOCALINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; THAPSIGARGIN; TRANSCRIPTION FACTOR CHOP; UNFOLDED PROTEIN RESPONSE;

EID: 84872493841     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.11.014     Document Type: Article

References (36)

1. Moasser M.M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26:6469-6487.
2. Garrett J.T., Olivares M.G., Rinehart C., Granja-Ingram N.D., Sanchez V., Chakrabarty A., Dave B., Cook R.S., Pao W., McKinely E., Manning H.C., Chang J., Arteaga C.L. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Natl. Acad. Sci. USA 2011, 108:5021-5026.
3. Tokunaga E., Kataoka A., Kimura Y., Oki E., Mashino K., Nishida K., Koga T., Morita M., Kakeji Y., Baba H., Ohno S., Maehara Y. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur. J. Cancer 2006, 42:629-635.
4. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., Karaca G., Troester M.A., Tse C.K., Edmiston S., Deming S.L., Geradts J., Cheang M.C., Nielsen T.O., Moorman P.G., Earp H.S., Millikan R.C. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, J. Am. Med. Assoc. 2006, 295:2492-2502.
5. Choi Y.H., Ahn J.H., Kim S.B., Jung K.H., Gong G.Y., Kim M.J., Son B.H., Ahn S.H., Kim W.K. Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Ann. Oncol.: Official J. Eur. Soc. Med. Oncol./ESMO 2009, 20:1337-1343.
6. Fendly B.M., Winget M., Hudziak R.M., Lipari M.T., Napier M.A., Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 1990, 50:1550-1558.
7. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760.
8. Ghosh R., Narasanna A., Wang S.E., Liu S., Chakrabarty A., Balko J.M., Gonzalez-Angulo A.M., Mills G.B., Penuel E., Winslow J., Sperinde J., Dua R., Pidaparthi S., Mukherjee A., Leitzel K., Kostler W.J., Lipton A., Bates M., Arteaga C.L. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011, 71:1871-1882.
9. Baselga J., Albanell J., Molina M.A., Arribas J. Mechanism of action of trastuzumab and scientific update. Semin. Oncol. 2001, 28:4-11.
10. Chan C.T., Metz M.Z., Kane S.E. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res. Treat. 2005, 91:187-201.
11. Nahta R., Yu D., Hung M.C., Hortobagyi G.N., Esteva F.J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol. 2006, 3:269-280.
12. Nahta R., Esteva F.J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006, 8:215.
13. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
14. Pohlmann P.R., Mayer I.A., Mernaugh R. Resistance to trastuzumab in Breast Cancer. Clin. Cancer Res. 2009, 15:7479-7491.
15. Scaltriti M., Rojo F., Ocana A., Anido J., Guzman M., Cortes J., Di Cosimo S., Matias-Guiu X., Ramon y Cajal S., Arribas J., Baselga J. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl. Cancer Inst. 2007, 99:628-638.
16. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., Klos K.S., Li P., Monia B.P., Nguyen N.T., Hortobagyi G.N., Hung M.C., Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
17. Harding H.P., Calfon M., Urano F., Novoa I., Ron D. Transcriptional and translational control in the mammalian unfolded protein response. Annu. Rev. Cell Dev. Biol. 2002, 18:575-599.
18. Walter P., Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011, 334:1081-1086.
19. Fu Y., Wey S., Wang M., Ye R., Liao C.P., Roy-Burman P., Lee A.S. Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium. Proc. Natl. Acad. Sci. USA 2008, 105:19444-19449.
20. Lee A.S., Hendershot L.M. ER stress and cancer. Cancer Biol. Ther. 2006, 5:721-722.
21. Scriven P., Coulson S., Haines R., Balasubramanian S., Cross S., Wyld L. Activation and clinical significance of the unfolded protein response in breast cancer. Br. J. Cancer 2009, 101:1692-1698.
22. Al-Rawashdeh F.Y., Scriven P., Cameron I.C., Vergani P.V., Wyld L. Unfolded protein response activation contributes to chemoresistance in hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 2010, 22:1099-1105.
23. Hraba-Renevey S., Turler H., Kress M., Salomon C., Weil R. SV40-induced expression of mouse gene 24p3 involves a post-transcriptional mechanism. Oncogene 1989, 4:601-608.
24. Mahadevan N.R., Rodvold J., Almanza G., Fernandez Perez A., Wheeler M.C., Zanetti M. ER stress activates Lipocalin 2 transcription in prostate cancer cells in an NF-kB-dependent manner. BMC Cancer 2011, 11:229.
25. Yamazaki H., Hiramatsu N., Hayakawa K., Tagawa Y., Okamura M., Ogata R., Huang T., Nakajima S., Yao J., Paton A.W., Paton J.C., Kitamura M. Activation of the Akt-NF-kappaB pathway by subtilase cytotoxin through the ATF6 branch of the unfolded protein response. J. Immunol. 2009, 183:1480-1487.
26. Rodvold J.J., Mahadevan N.R., Zanetti M. Lipocalin 2 in cancer: When good immunity goes bad. Cancer Lett. 2011.
27. Yang J., Bielenberg D.R., Rodig S.J., Doiron R., Clifton M.C., Kung A.L., Strong R.K., Zurakowski D., Moses M.A. Lipocalin 2 promotes breast cancer progression. Proc. Natl. Acad. Sci. USA 2009, 106:3913-3918.
28. Aldridge J.R., Moseley C.E., Boltz D.A., Negovetich N.J., Reynolds C., Franks J., Brown S.A., Doherty P.C., Webster R.G., Thomas P.G. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc. Natl. Acad. Sci. USA 2009, 106:5306-5311.
29. Berger T., Cheung C.C., Elia A.J., Mak T.W. Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis. Proc. Natl. Acad. Sci. USA 2010, 107:2995-3000.
30. Sagara Y., Inesi G. Inhibition of the sarcoplasmic reticulum Ca2+ transport ATPase by thapsigargin at subnanomolar concentrations. J. Biol. Chem. 1991, 266:13503-13506.
31. Ozcan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R.O., Gorgun C.Z., Hotamisligil G.S. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313:1137-1140.
32. Vlahos C.J., Matter W.F., Hui K.Y., Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 1994, 269:5241-5248.
33. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chene P., De Pover A., Schoemaker K., Fabbro D., Gabriel D., Simonen M., Murphy L., Finan P., Sellers W., Garcia-Echeverria C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008, 7:1851-1863.
34. Komurov K., Tseng J.T., Muller M., Seviour E.G., Moss T.J., Yang L., Nagrath D., Ram P.T. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol. Syst. Biol. 2012, 8:596.
35. Leng X., Ding T., Lin H., Wang Y., Hu L., Hu J., Feig B., Zhang W., Pusztai L., Symmans W.F., Wu Y., Arlinghaus R.B. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res. 2009, 69:8579-8584.
36. Pandolfi P.P. Breast cancer - loss of PTEN predicts resistance to treatment. N. Engl. J. Med. 2004, 351:2337-2338.